Severe immune thrombocytopenia following COVID-19 vaccination (Moderna) and immune checkpoint inhibitor
Safe and effective prophylactic vaccines are urgently needed to contain the coronavirus disease 2019 (COVID-19) pandemic. However, several vaccination-related adverse effects have been reported. Here, we report a rare case of severe immune thrombocytopenia occurring 3 days after receiving the mRNA-1...
Saved in:
| Published in | The American journal of emergency medicine Vol. 56; pp. 395.e1 - 395.e3 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.06.2022
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Safe and effective prophylactic vaccines are urgently needed to contain the coronavirus disease 2019 (COVID-19) pandemic. However, several vaccination-related adverse effects have been reported. Here, we report a rare case of severe immune thrombocytopenia occurring 3 days after receiving the mRNA-1273 (Moderna) COVID-19 vaccine in an Asian woman with a history of refractory lung adenocarcinoma treated with durvalumab, an immune checkpoint inhibitor. Treatment with platelet transfusion (12 units) and oral prednisolone (1 mg/kg per day) significantly improved her hemoptysis with thrombocytopenia. To the best of our knowledge, this is the first case of ITP following Moderna inoculation among Asians. This study highlights a potential adverse effect of mRNA-based COVID-19 vaccines in cancer patients receiving immune checkpoint inhibitors. |
|---|---|
| AbstractList | Safe and effective prophylactic vaccines are urgently needed to contain the coronavirus disease 2019 (COVID-19) pandemic. However, several vaccination-related adverse effects have been reported. Here, we report a rare case of severe immune thrombocytopenia occurring 3 days after receiving the mRNA-1273 (Moderna) COVID-19 vaccine in an Asian woman with a history of refractory lung adenocarcinoma treated with durvalumab, an immune checkpoint inhibitor. Treatment with platelet transfusion (12 units) and oral prednisolone (1 mg/kg per day) significantly improved her hemoptysis with thrombocytopenia. To the best of our knowledge, this is the first case of ITP following Moderna inoculation among Asians. This study highlights a potential adverse effect of mRNA-based COVID-19 vaccines in cancer patients receiving immune checkpoint inhibitors. Safe and effective prophylactic vaccines are urgently needed to contain the coronavirus disease 2019 (COVID-19) pandemic. However, several vaccination-related adverse effects have been reported. Here, we report a rare case of severe immune thrombocytopenia occurring 3 days after receiving the mRNA-1273 (Moderna) COVID-19 vaccine in an Asian woman with a history of refractory lung adenocarcinoma treated with durvalumab, an immune checkpoint inhibitor. Treatment with platelet transfusion (12 units) and oral prednisolone (1 mg/kg per day) significantly improved her hemoptysis with thrombocytopenia. To the best of our knowledge, this is the first case of ITP following Moderna inoculation among Asians. This study highlights a potential adverse effect of mRNA-based COVID-19 vaccines in cancer patients receiving immune checkpoint inhibitors.Safe and effective prophylactic vaccines are urgently needed to contain the coronavirus disease 2019 (COVID-19) pandemic. However, several vaccination-related adverse effects have been reported. Here, we report a rare case of severe immune thrombocytopenia occurring 3 days after receiving the mRNA-1273 (Moderna) COVID-19 vaccine in an Asian woman with a history of refractory lung adenocarcinoma treated with durvalumab, an immune checkpoint inhibitor. Treatment with platelet transfusion (12 units) and oral prednisolone (1 mg/kg per day) significantly improved her hemoptysis with thrombocytopenia. To the best of our knowledge, this is the first case of ITP following Moderna inoculation among Asians. This study highlights a potential adverse effect of mRNA-based COVID-19 vaccines in cancer patients receiving immune checkpoint inhibitors. AbstractSafe and effective prophylactic vaccines are urgently needed to contain the coronavirus disease 2019 (COVID-19) pandemic. However, several vaccination-related adverse effects have been reported. Here, we report a rare case of severe immune thrombocytopenia occurring 3 days after receiving the mRNA-1273 (Moderna) COVID-19 vaccine in an Asian woman with a history of refractory lung adenocarcinoma treated with durvalumab, an immune checkpoint inhibitor. Treatment with platelet transfusion (12 units) and oral prednisolone (1 mg/kg per day) significantly improved her hemoptysis with thrombocytopenia. To the best of our knowledge, this is the first case of ITP following Moderna inoculation among Asians. This study highlights a potential adverse effect of mRNA-based COVID-19 vaccines in cancer patients receiving immune checkpoint inhibitors. |
| Author | Lien, Wan-Ching Lin, Chien-Chin Chong, Kah-Meng Yang, Ching-Yao |
| Author_xml | – sequence: 1 givenname: Kah-Meng surname: Chong fullname: Chong, Kah-Meng organization: Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan – sequence: 2 givenname: Ching-Yao surname: Yang fullname: Yang, Ching-Yao organization: Division of Pulmonology, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan – sequence: 3 givenname: Chien-Chin surname: Lin fullname: Lin, Chien-Chin organization: Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan – sequence: 4 givenname: Wan-Ching surname: Lien fullname: Lien, Wan-Ching email: dtemer17@yahoo.com.tw organization: Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35339338$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUltr2zAYFaNjTbP9gT0Mw166B2e62JYyRmFkt0JHH1r2KmTpc6LUljLJzsi_n7w0ZQusAyGBdM7R4ZzvDJ047wChlwTPCCbV2_VMraGbUUzpDLO08BM0ISWjuSCcnKAJ5qzMK17yU3QW4xpjQoqyeIZOWcnYnDExQcsb2EKAzHbd4CDrV8F3tde73m_AWZU1vm39T-uW2eL6--XHnMyzrdLaOtVb77Lzb95AcOpNppw5iOgV6LuNt67PrFvZ2vY-PEdPG9VGeHF_TtHt50-3i6_51fWXy8WHq1yXYt7nStWFaZIzbgyuFNeibBRt5kAr2oDivKmrRtB0iblhouYEK17hwqTNlA2boou97GaoOzAaXB9UKzfBdirspFdW_v3i7Eou_VaKOaMYiyRwfi8Q_I8BYi87GzW0rXLghyhpVRSsoiTFN0Wvj6BrP6Qs2hGVYEQUCTtFr_509GDlUEECiD1ABx9jgEZq2_9ONxm0rSRYjm3LtRzblmPbErO0cKLSI-pB_VHS-z0JUg1bC0FGbcFpMDaA7qXx9nH6xRFdt9ZZrdo72EF8iIDImDjyZpzBcQRpipcIwZPAu38L_O_3XyN07Og |
| CitedBy_id | crossref_primary_10_1111_ejh_13917 crossref_primary_10_1002_rmv_2495 crossref_primary_10_35420_jcohns_2022_33_2_92 crossref_primary_10_4291_wjgp_v13_i5_157 crossref_primary_10_1016_j_ajem_2022_03_055 crossref_primary_10_1016_j_intimp_2024_111606 crossref_primary_10_1002_ccr3_9070 crossref_primary_10_1159_000541550 crossref_primary_10_1016_j_heliyon_2022_e12125 crossref_primary_10_1038_s41419_023_05922_w crossref_primary_10_1007_s40278_022_17034_2 crossref_primary_10_3390_vaccines10091444 |
| Cites_doi | 10.1016/j.vaccine.2021.04.054 10.1002/ijc.33822 10.1056/NEJMoa2104882 10.1002/ccr3.4227 10.1038/s41591-021-01419-1 10.4161/hv.23601 10.2147/JBM.S307047 10.1016/j.ejca.2019.07.014 10.1097/HS9.0000000000000618 10.1002/ajh.26132 10.1001/jamacardio.2021.2833 10.1016/j.annemergmed.2021.02.011 10.1016/j.idcr.2021.e01344 10.1002/ajh.26106 10.3389/fonc.2020.530478 10.1182/blood-2010-08-302984 10.1136/bcr-2021-242220 10.2217/fon-2021-0288 |
| ContentType | Journal Article |
| Copyright | 2022 Elsevier Inc. Elsevier Inc. Copyright © 2022 Elsevier Inc. All rights reserved. 2022. Elsevier Inc. 2022 Elsevier Inc. All rights reserved. 2022 Elsevier Inc. |
| Copyright_xml | – notice: 2022 Elsevier Inc. – notice: Elsevier Inc. – notice: Copyright © 2022 Elsevier Inc. All rights reserved. – notice: 2022. Elsevier Inc. – notice: 2022 Elsevier Inc. All rights reserved. 2022 Elsevier Inc. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7T5 7X7 7XB 88E 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 K9. KB0 M0S M1P M2O MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM |
| DOI | 10.1016/j.ajem.2022.03.030 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Research Library Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Central China ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Research Library Prep MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1532-8171 |
| EndPage | 395.e3 |
| ExternalDocumentID | PMC8932008 35339338 10_1016_j_ajem_2022_03_030 S0735675722001887 1_s2_0_S0735675722001887 |
| Genre | Case Reports |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 23M 354 4.4 457 4G. 53G 5RE 5VS 6J9 7-5 71M 7RV 7X7 88E 8F7 8FI 8FJ 8G5 8P~ 9JM A8Z AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABUWG ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIWK ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFFNX AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN AZQEC BENPR BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI C45 CAG CCPQU COF CS3 DWQXO EBS EFJIC EFKBS EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HDV HMCUK HMK HMO HVGLF HZ~ IHE J1W K-O KOM LX1 M1P M29 M2O M41 MO0 N4W N9A NAPCQ O-L O9- OAUVE OBH OB~ OHH OM0 OVD OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO Q38 R2- ROL RPZ SAE SDF SDG SDP SEL SES SEW SJN SPCBC SSH SSZ SV3 T5K TEORI UAP UHS UKHRP UNMZH UV1 WOW WUQ Z5R ZGI ZY1 ~G- 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW PKN RIG AAIAV ABLVK ABYKQ AJBFU EFLBG ESTFP LCYCR AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7T5 7XB 8FK H94 K9. MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c589t-aab4df3387dd06a7c85fa2f9e262fea77fb6f825fa07d38b710a7604d760d5f3 |
| IEDL.DBID | .~1 |
| ISSN | 0735-6757 1532-8171 |
| IngestDate | Thu Aug 21 18:28:00 EDT 2025 Fri Jul 11 09:59:38 EDT 2025 Wed Aug 13 05:13:14 EDT 2025 Wed Feb 19 02:25:43 EST 2025 Tue Jul 01 03:01:18 EDT 2025 Thu Apr 24 23:01:25 EDT 2025 Fri Feb 23 02:39:38 EST 2024 Tue Feb 25 20:01:41 EST 2025 Tue Aug 26 17:45:01 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | COVID-19 Moderna vaccine Immune checkpoint inhibitors mRNA-based vaccine Immune thrombocytopenia |
| Language | English |
| License | Copyright © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c589t-aab4df3387dd06a7c85fa2f9e262fea77fb6f825fa07d38b710a7604d760d5f3 |
| Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-4 ObjectType-Report-1 ObjectType-Article-3 content type line 23 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8932008 |
| PMID | 35339338 |
| PQID | 2664418444 |
| PQPubID | 1216387 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8932008 proquest_miscellaneous_2644362139 proquest_journals_2664418444 pubmed_primary_35339338 crossref_citationtrail_10_1016_j_ajem_2022_03_030 crossref_primary_10_1016_j_ajem_2022_03_030 elsevier_sciencedirect_doi_10_1016_j_ajem_2022_03_030 elsevier_clinicalkeyesjournals_1_s2_0_S0735675722001887 elsevier_clinicalkey_doi_10_1016_j_ajem_2022_03_030 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-06-01 |
| PublicationDateYYYYMMDD | 2022-06-01 |
| PublicationDate_xml | – month: 06 year: 2022 text: 2022-06-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Philadelphia |
| PublicationTitle | The American journal of emergency medicine |
| PublicationTitleAlternate | Am J Emerg Med |
| PublicationYear | 2022 |
| Publisher | Elsevier Inc Elsevier Limited |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier Limited |
| References | Cecinati, Principi, Brescia (bb0025) 2013; 9 Julian, Mathern, Fernando (bb0045) 2021; 77 Qasim, Ali, Yassin (bb0120) 2021; 26 Lee, Cines, Gernsheimer (bb0030) 2021; 96 Bristol-Myers Squibb Company (bb0085) 2022 Luo, Li, Hou (bb0110) 2021; 17 Tarawneh, Tarawneh (bb0060) 2021; 96 Helms, Ansteatt, Roberts (bb0035) 2021; 12 Malayala, Mohan, Vasireddy (bb0040) 2021; 13 Neunert, Lim, Crowther (bb0015) 2011; 117 Welsh, Baumblatt, Chege (bb0070) 2021; 39 Schultz, Sorvoll, Michelsen (bb0005) 2021; 384 Yiqing Huang, Soon, Aminkeng (bb0105) 2022; 150 Michot, Lazarovici, Tieu (bb0115) 2019; 122 Dougherty, Lynch, Hall (bb0080) 2021; 9 AstraZeneca Pharmaceuticals LP (bb0100) 2022 Bristol-Myers Squibb Company (bb0090) 2022 Chezi Ganzel (bb0065) 2021; 23 Pishko, Bussel, Cines (bb0020) 2021; 27 Gaignard, Lieberherr, Schoenenberger (bb0055) 2021; 5 Liu, Liang, Liang (bb0075) 2020; 10 Fueyo-Rodriguez, Valente-Acosta, Jimenez-Soto (bb0050) 2021; 14 Merck Sharp & Dohme Corp (bb0095) 2022 Montgomery, Ryan, Engler (bb0010) 2021 Dougherty (10.1016/j.ajem.2022.03.030_bb0080) 2021; 9 Bristol-Myers Squibb Company (10.1016/j.ajem.2022.03.030_bb0085) 2022 Merck Sharp & Dohme Corp (10.1016/j.ajem.2022.03.030_bb0095) 2022 Montgomery (10.1016/j.ajem.2022.03.030_bb0010) 2021 Yiqing Huang (10.1016/j.ajem.2022.03.030_bb0105) 2022; 150 AstraZeneca Pharmaceuticals LP (10.1016/j.ajem.2022.03.030_bb0100) 2022 Bristol-Myers Squibb Company (10.1016/j.ajem.2022.03.030_bb0090) 2022 Qasim (10.1016/j.ajem.2022.03.030_bb0120) 2021; 26 Julian (10.1016/j.ajem.2022.03.030_bb0045) 2021; 77 Malayala (10.1016/j.ajem.2022.03.030_bb0040) 2021; 13 Neunert (10.1016/j.ajem.2022.03.030_bb0015) 2011; 117 Michot (10.1016/j.ajem.2022.03.030_bb0115) 2019; 122 Gaignard (10.1016/j.ajem.2022.03.030_bb0055) 2021; 5 Cecinati (10.1016/j.ajem.2022.03.030_bb0025) 2013; 9 Liu (10.1016/j.ajem.2022.03.030_bb0075) 2020; 10 Helms (10.1016/j.ajem.2022.03.030_bb0035) 2021; 12 Schultz (10.1016/j.ajem.2022.03.030_bb0005) 2021; 384 Chezi Ganzel (10.1016/j.ajem.2022.03.030_bb0065) 2021; 23 Pishko (10.1016/j.ajem.2022.03.030_bb0020) 2021; 27 Fueyo-Rodriguez (10.1016/j.ajem.2022.03.030_bb0050) 2021; 14 Lee (10.1016/j.ajem.2022.03.030_bb0030) 2021; 96 Luo (10.1016/j.ajem.2022.03.030_bb0110) 2021; 17 Tarawneh (10.1016/j.ajem.2022.03.030_bb0060) 2021; 96 Welsh (10.1016/j.ajem.2022.03.030_bb0070) 2021; 39 35437199 - Am J Emerg Med. 2022 Aug;58:337 |
| References_xml | – volume: 27 start-page: 1145 year: 2021 end-page: 1146 ident: bb0020 article-title: COVID-19 vaccination and immune thrombocytopenia publication-title: Nat Med – volume: 5 year: 2021 ident: bb0055 article-title: Autoimmune hematologic disorders in two patients after mRNA COVID-19 vaccine publication-title: Hemasphere – volume: 77 start-page: 654 year: 2021 end-page: 656 ident: bb0045 article-title: Idiopathic thrombocytopenic Purpura and the Moderna Covid-19 vaccine publication-title: Ann Emerg Med – volume: 150 start-page: 636 year: 2022 end-page: 644 ident: bb0105 article-title: Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients publication-title: Int J Cancer – volume: 17 start-page: 3477 year: 2021 end-page: 3484 ident: bb0110 article-title: Indications for and contraindications of immune checkpoint inhibitors in cancer patients with coronavirus disease 2019 vaccination publication-title: Future Oncol – volume: 9 year: 2021 ident: bb0080 article-title: Drug-induced immune-mediated thrombocytopenia secondary to durvalumab use publication-title: Clin Case Rep – year: 2022 ident: bb0085 article-title: YERVOY (ipilimumab) – volume: 96 start-page: 534 year: 2021 end-page: 537 ident: bb0030 article-title: Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination publication-title: Am J Hematol – volume: 384 start-page: 2124 year: 2021 end-page: 2130 ident: bb0005 article-title: Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination publication-title: N Engl J Med – volume: 9 start-page: 1158 year: 2013 end-page: 1162 ident: bb0025 article-title: Vaccine administration and the development of immune thrombocytopenic purpura in children publication-title: Hum Vaccin Immunother – volume: 13 year: 2021 ident: bb0040 article-title: Purpuric rash and thrombocytopenia after the mRNA-1273 (Moderna) COVID-19 vaccine publication-title: Cureus – volume: 12 start-page: 221 year: 2021 end-page: 224 ident: bb0035 article-title: Severe, refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccine publication-title: J Blood Med – year: 2021 ident: bb0010 article-title: Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military publication-title: JAMA Cardiol – volume: 10 year: 2020 ident: bb0075 article-title: Immune thrombocytopenia induced by immune checkpoint inhibitors in solid cancer: case report and literature review publication-title: Front Oncol – year: 2022 ident: bb0095 article-title: KEYTRUDA (pembrolizumab) – volume: 39 start-page: 3329 year: 2021 end-page: 3332 ident: bb0070 article-title: Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the vaccine adverse event reporting system (VAERS) publication-title: Vaccine – volume: 14 year: 2021 ident: bb0050 article-title: Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination publication-title: BMJ Case Rep – year: 2022 ident: bb0100 article-title: IMFINZI (durvalumab) – volume: 96 year: 2021 ident: bb0060 article-title: Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine publication-title: Am J Hematol – volume: 26 year: 2021 ident: bb0120 article-title: Immune thrombocytopenia relapse post covid-19 vaccine in young male patient publication-title: IDCases – volume: 23 start-page: 341 year: 2021 ident: bb0065 article-title: Immune thrombocytopenia following the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine publication-title: IMAJ – volume: 117 start-page: 4190 year: 2011 end-page: 4207 ident: bb0015 article-title: The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia publication-title: Blood – volume: 122 start-page: 72 year: 2019 end-page: 90 ident: bb0115 article-title: Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? publication-title: Eur J Cancer – year: 2022 ident: bb0090 article-title: OPDIVO (nivolumab) – volume: 39 start-page: 3329 issue: 25 year: 2021 ident: 10.1016/j.ajem.2022.03.030_bb0070 article-title: Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the vaccine adverse event reporting system (VAERS) publication-title: Vaccine doi: 10.1016/j.vaccine.2021.04.054 – year: 2022 ident: 10.1016/j.ajem.2022.03.030_bb0085 – volume: 150 start-page: 636 issue: 4 year: 2022 ident: 10.1016/j.ajem.2022.03.030_bb0105 article-title: Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients publication-title: Int J Cancer doi: 10.1002/ijc.33822 – volume: 384 start-page: 2124 issue: 22 year: 2021 ident: 10.1016/j.ajem.2022.03.030_bb0005 article-title: Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination publication-title: N Engl J Med doi: 10.1056/NEJMoa2104882 – volume: 9 issue: 6 year: 2021 ident: 10.1016/j.ajem.2022.03.030_bb0080 article-title: Drug-induced immune-mediated thrombocytopenia secondary to durvalumab use publication-title: Clin Case Rep doi: 10.1002/ccr3.4227 – volume: 27 start-page: 1145 issue: 7 year: 2021 ident: 10.1016/j.ajem.2022.03.030_bb0020 article-title: COVID-19 vaccination and immune thrombocytopenia publication-title: Nat Med doi: 10.1038/s41591-021-01419-1 – volume: 9 start-page: 1158 issue: 5 year: 2013 ident: 10.1016/j.ajem.2022.03.030_bb0025 article-title: Vaccine administration and the development of immune thrombocytopenic purpura in children publication-title: Hum Vaccin Immunother doi: 10.4161/hv.23601 – year: 2022 ident: 10.1016/j.ajem.2022.03.030_bb0100 – volume: 12 start-page: 221 year: 2021 ident: 10.1016/j.ajem.2022.03.030_bb0035 article-title: Severe, refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccine publication-title: J Blood Med doi: 10.2147/JBM.S307047 – year: 2022 ident: 10.1016/j.ajem.2022.03.030_bb0090 – volume: 122 start-page: 72 year: 2019 ident: 10.1016/j.ajem.2022.03.030_bb0115 article-title: Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? publication-title: Eur J Cancer doi: 10.1016/j.ejca.2019.07.014 – volume: 5 issue: 8 year: 2021 ident: 10.1016/j.ajem.2022.03.030_bb0055 article-title: Autoimmune hematologic disorders in two patients after mRNA COVID-19 vaccine publication-title: Hemasphere doi: 10.1097/HS9.0000000000000618 – volume: 96 start-page: 534 issue: 5 year: 2021 ident: 10.1016/j.ajem.2022.03.030_bb0030 article-title: Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination publication-title: Am J Hematol doi: 10.1002/ajh.26132 – year: 2021 ident: 10.1016/j.ajem.2022.03.030_bb0010 article-title: Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2021.2833 – volume: 77 start-page: 654 issue: 6 year: 2021 ident: 10.1016/j.ajem.2022.03.030_bb0045 article-title: Idiopathic thrombocytopenic Purpura and the Moderna Covid-19 vaccine publication-title: Ann Emerg Med doi: 10.1016/j.annemergmed.2021.02.011 – volume: 23 start-page: 341 year: 2021 ident: 10.1016/j.ajem.2022.03.030_bb0065 article-title: Immune thrombocytopenia following the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine publication-title: IMAJ – volume: 26 year: 2021 ident: 10.1016/j.ajem.2022.03.030_bb0120 article-title: Immune thrombocytopenia relapse post covid-19 vaccine in young male patient publication-title: IDCases doi: 10.1016/j.idcr.2021.e01344 – volume: 13 issue: 3 year: 2021 ident: 10.1016/j.ajem.2022.03.030_bb0040 article-title: Purpuric rash and thrombocytopenia after the mRNA-1273 (Moderna) COVID-19 vaccine publication-title: Cureus – volume: 96 issue: 5 year: 2021 ident: 10.1016/j.ajem.2022.03.030_bb0060 article-title: Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine publication-title: Am J Hematol doi: 10.1002/ajh.26106 – year: 2022 ident: 10.1016/j.ajem.2022.03.030_bb0095 – volume: 10 year: 2020 ident: 10.1016/j.ajem.2022.03.030_bb0075 article-title: Immune thrombocytopenia induced by immune checkpoint inhibitors in solid cancer: case report and literature review publication-title: Front Oncol doi: 10.3389/fonc.2020.530478 – volume: 117 start-page: 4190 issue: 16 year: 2011 ident: 10.1016/j.ajem.2022.03.030_bb0015 article-title: The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia publication-title: Blood doi: 10.1182/blood-2010-08-302984 – volume: 14 issue: 5 year: 2021 ident: 10.1016/j.ajem.2022.03.030_bb0050 article-title: Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination publication-title: BMJ Case Rep doi: 10.1136/bcr-2021-242220 – volume: 17 start-page: 3477 issue: 26 year: 2021 ident: 10.1016/j.ajem.2022.03.030_bb0110 article-title: Indications for and contraindications of immune checkpoint inhibitors in cancer patients with coronavirus disease 2019 vaccination publication-title: Future Oncol doi: 10.2217/fon-2021-0288 – reference: 35437199 - Am J Emerg Med. 2022 Aug;58:337 |
| SSID | ssj0011454 |
| Score | 2.3772268 |
| Snippet | Safe and effective prophylactic vaccines are urgently needed to contain the coronavirus disease 2019 (COVID-19) pandemic. However, several vaccination-related... AbstractSafe and effective prophylactic vaccines are urgently needed to contain the coronavirus disease 2019 (COVID-19) pandemic. However, several... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 395.e1 |
| SubjectTerms | Adenocarcinoma Asian people Blood platelets Cancer vaccines Coronaviruses COVID-19 COVID-19 vaccines COVID-19 Vaccines - adverse effects Emergency Emergency medical care Female Hemoptysis Hepatitis Humans Idiopathic thrombocytopenic purpura Immune Checkpoint Inhibitors Immune thrombocytopenia Immunotherapy Inoculation Lung cancer Moderna vaccine Monoclonal antibodies mRNA mRNA-based vaccine Pandemics Patients Prednisolone Purpura, Thrombocytopenic, Idiopathic - chemically induced Purpura, Thrombocytopenic, Idiopathic - drug therapy Side effects Targeted cancer therapy Thrombocytopenia Thrombocytopenia - chemically induced Vaccination - adverse effects Vaccines |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELagSIgL4k2gICNxAKGIrJ_JCaFCVZAKhxa0N8vxg6ZAsnRTEP-emcQJFKpFivYST7LJjGc-x9_MEPJYORYkeLlcKQkLlOAWeV0Lj8Q1zisXhfOYO7z_Tu19EG-Xcpk-uK0TrXLyiYOj9p3Db-TPIZBA5C6FEC9W33LsGoW7q6mFxkVyCUuXIaVLL-cFF0D9oQsaWDES7KVOSTMjv8seB8xEZ2wocoos6PMD07_A82_-5B8BafcauZqQJH05qv46uRDaG-Tyftorv0k-HQQw00AbzAAJFPshfK0797PHhlmNpREsoPsBkYvuvP_45lW-qOh360B20BV9MnZJs0-pbf10EdCw-7zqmranTXvU1OAOTm6Rw93Xhzt7eWqrkDtZVn1uLSgjwtJUe18oq10po2WxCkyxGKzWsVYRFo7RFtrzsgYMYrUqhIcfLyO_Tbbarg13CcUk2hCtsjZifmpdeoAjMjLBQ2Sh5BlZTK_UuFRyHDtffDETt-zYoBoMqsEUHI4iI89mmdVYcGPjaD5pykyppOD8DMSDjVL6PKmwTvN3bRZmDYPNAZoOWg5D6hn444zIWTJBlBF6_PeO25MZmfkmv006I4_m0zC9cc_GtqE7xTFCAMYAnJ6RO6PVza-FA1SvQI_wOGfscR6ApcPPnmmbo6GEOKBUJL7c2_y37pMr-AwjM26bbPUnp-EBYLC-fjhMtF-v2jDj priority: 102 providerName: ProQuest |
| Title | Severe immune thrombocytopenia following COVID-19 vaccination (Moderna) and immune checkpoint inhibitor |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0735675722001887 https://www.clinicalkey.es/playcontent/1-s2.0-S0735675722001887 https://dx.doi.org/10.1016/j.ajem.2022.03.030 https://www.ncbi.nlm.nih.gov/pubmed/35339338 https://www.proquest.com/docview/2664418444 https://www.proquest.com/docview/2644362139 https://pubmed.ncbi.nlm.nih.gov/PMC8932008 |
| Volume | 56 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELemTUK8IMZnYExG4gGEQlPbiZPHrWzqQCuIDdQ3y_HHlgFJtWYgXva3c5cvUTYNCalK1eauaXzn88_K7-4IeZEY5mKIcmGSxLBBcWYc5rmwSFzjPDNeGIu5w4ezZPpZvJvH8zUy6XNhkFbZxf42pjfRuvtm1I3maFEUoyNwzhjgrmRIC4K5ghnsQqKXv7kcaB4A95tOaCgconSXONNyvPSZw2x0xppCp8iEvn5xugo-_-ZQ_rEo7d8ldzo0SXfaP7xJ1lx5j9w67J6X3ycnRw5c1dECs0AcxZ4I3_PK_KqxaVahqQcvqH7C6kUnH74cvA3HGf2hDeg29qIv205p-hXVpe1_BKxsvi6qoqxpUZ4WOYSE8wfkeH_veDINu9YKoYnTrA61BoN42J5Ka6NES5PGXjOfOZYw77SUPk88bB69jqTlaQ44RMskEhYONvb8IVkvq9I9JhQTaZ3XidYec1Tz1AIkiT0T3HnmUh6QcT-kynRlx7H7xTfV88vOFJpBoRlUxOEVBeT1oLNoi27cKM17S6k-nRQCoII14UYteZ2WW3ZzeKnGagnC6oqfBSQeNFdc9Z9X3OrdSA0XAXwEgDQVQgTk-XAapjg-t9Glqy5QRgjAGYDVA_Ko9bphWDjA9QzsCLez4o-DAJYPXz1TFqdNGXFAqkh-efKft_OU3MZPLW1ui6zX5xfuGQC0Ot9uZiAc5Vxuk42dg_fTGbzv7s0-fvoNvJI9vw |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwEB6VrQS8IG4WChgJJBCKSBznekAIemiXdhdEF9Q3y3FsmgLJ0k2p-qP4j8zkgkK1PFWK8hJPDs83VzzjAXgcam4C1HJOGAYYoBjtOWkqMkpc8_1EW6Ezqh2eTMPRR_F2L9hbgZ9dLQylVXY6sVbUWanpH_kLNCRouWMhxKv5d4e6RtHqatdCo4HFtjk5xpBt8XK8gfx9wvnW5mx95LRdBRwdxEnlKIXvYjEyi7LMDVWk48AqbhPDQ26NiiKbhhbjJqvcKPPjFE2wikJXZHjKAuvjbS_AqvAxkhnA6pvN6fsP_bKFJ-q2ayg2lNEfRG2VTpNQpg4Mlb5zXu-qSmnXZ1vCfz3dvxM2_7CAW1fhSuu6stcN1q7Biimuw8VJuzh_Az7vGpQLw3IqOTGMGjB8S0t9UlGHrlwxi5Arj9FUsvV3n8YbjpewH0ojbQ0O9rRpy6aeMVVk3U0QUvrLvMyLiuXFfp6i_jm8CbPzmPFbMCjKwtwBRlW7xqpQKUsFsWmcof8TWC58Y7mJ_SF43ZRK3e5xTq02vsoume1AEhsksUG6Ph7uEJ73NPNmh4-lo_2OU7KrXUVtK9EALaWKzqIyi1ZhLKQnFzhY7hJ0CDmcct3QAAwh6Clbn6jxdf77xLUORrJ_yG8ZGsKj_jLqE1okUoUpj2iMQGxzDAyGcLtBXT8tPsYGCfIRP-cUHvsBtFf56StFvl_vWY5uMWXa3F3-Wg_h0mg22ZE74-n2PbhM39Ok5a3BoDo8MvfRAazSB63YMZDnLOi_AOAhb8Q |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9RAFB5qheKLeDdadQQFRUKTyUwmeRCRrkvX2iq0yr4Nk7nYVE3W7tbSn-a_85zctFrWp0LIS-bkMuee-c4cQp6khjkBVi5MUwEJijNxWBTcInAtSXLjubFYO7yzm2595G-nYrpCfva1MAir7G1iY6htbfAf-QY4EvDcGed8w3ewiA-j8avZ9xA7SOFKa99OoxWRbXd6Aunb_OVkBLx-ytj4zf7mVth1GAiNyPJFqDW8l4csTVobpVqaTHjNfO5YyrzTUvoi9ZBDeR1Jm2QFuGMt04hbOFnhE7jtJXJZJiJGFZPTIdeDLKNpwAYKhNh-Ibt6nRZapg8dFsEz1uyvigDs833ivzHv39DNP3zh-Bq52gWx9HUrddfJiqtukLWdbpn-Jvm850BDHC2x-MRRbMXwrajN6QJ7dZWaehC--gScJt18_2kyCuOc_tAGaBsxoc_aBm36OdWV7W8CwmW-zOqyWtCyOigLsERHt8j-Rcz3bbJa1ZW7SyjW7zqvU609lsYWmYVISHjGE-eZy5KAxP2UKtPtdo5NN76qHtZ2qJANCtmgogSOKCAvBppZu9fH0tFJzynVV7GC3VXgipZSyfOo3LwzHXMVqzkMVnsoOig5DFFv4AoCIgbKLjpqo57_PnG9FyM1POS3NgXk8XAZLAsuF-nK1cc4hnMIbyBFCMidVuqGaUkgS8iBj_A5Z-RxGIC7lp-9UpUHze7lECAj5ube8td6RNZAvdW7ye72fXIFP6fF562T1cXRsXsAkeCieNjoHCXqgnX8F8AacpQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Severe+immune+thrombocytopenia+following+COVID-19+vaccination+%28Moderna%29+and+immune+checkpoint+inhibitor&rft.jtitle=The+American+journal+of+emergency+medicine&rft.au=Chong%2C+Kah-Meng&rft.au=Yang%2C+Ching-Yao&rft.au=Lin%2C+Chien-Chin&rft.au=Lien%2C+Wan-Ching&rft.date=2022-06-01&rft.eissn=1532-8171&rft.volume=56&rft.spage=395.e1&rft_id=info:doi/10.1016%2Fj.ajem.2022.03.030&rft_id=info%3Apmid%2F35339338&rft.externalDocID=35339338 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F07356757%2FS0735675722X00041%2Fcov150h.gif |